When lung cancer cells are treated with DZNep followed by DAC exposure, they are specifically recognized and lysed by allogeneic lymphocytes that express recombinant T cell receptors and recognize NY-ESO-1 and MAGE-A3, suggesting that a combination of DNA demethylating agents with histone demethylation drugs may provide a synergistic effect that induces CTA expression, which can be used as an adjunct to adoptive cancer immunotherapy (111). The gene discussed is CTAG1B; the disease is lung cancer.